Nektar Therapeutics (NKTR)
39.71
-1.73
(-4.17%)
USD |
NASDAQ |
Jan 09, 16:00
39.70
-0.01
(-0.03%)
After-Hours: 20:00
Nektar Therapeutics Research and Development Expense (Quarterly): 27.25M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Rigel Pharmaceuticals, Inc. | 7.353M |
| Insmed, Inc. | 186.42M |
| Eli Lilly & Co. | 3.466B |
| Ironwood Pharmaceuticals, Inc. | 21.99M |
| Lyell Immunopharma, Inc. | 25.61M |